Santilli 2015.

Methods	Allocation: randomised Intervention model: parallel assignment Masking: open label
Participants	Condition: impaired glucose tolerance, impaired fasting glucose or newly diagnosed T2DM Enrolment: 29 Inclusion criteria: metformin‐treated obese participants with impaired glucose tolerance, impaired fasting glucose or newly diagnosed T2DM Exclusion criteria: NR
Interventions	Intervention(s): liraglutide, subcutaneous Comparator (s): placebo Duration of intervention: 4 months
Outcomes	Primary outcomes: not specified, assume: change in subcutaneous fat and visceral adipose tissue Secondary outcomes: not specified, assume: degree of non‐alcoholic fatty liver disease, weight loss, insulin sensitivity, β‐cell performance, C‐reactive protein, leptin, glycaemic measures
Study details	Trial terminated early: no
Publication details	Language of publication: English Funding: NR Publication status: abstract
Stated aim of study	Quote: "... we hypothesized that this class of drugs may exert additional cardiometabolic actions on top of those anticipated for lifestyle intervention‐mediated weight loss."
Notes	Separate data for participants with intermediate hyperglycaemia are not yet available, but will be provided from the authors when the full article is published